BPGbio, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, announced today the publication of a significant, multi-year research effort titled “Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced its participation in both the US Pharma Partnering Summit, scheduled for May 14-15, 2024, in San Diego and the EU Pharma Partnering Summit taking place May 22-23, 2024 in Basel, Switzerland. 

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico. The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.

Lincoln Property Company (“Lincoln”), Cresa Boston, and BPGbio, Inc, a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that BPGbio has leased approx. 70,000 sq. ft. of lab and office space at 300 Third Avenue in Waltham, Mass. The company plans to relocate its headquarters from Framingham and expand into two full floors of the new space circa June 2025, significantly increasing its footprint in the Boston region.

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the appointment of Ritesh Srivastava as General Counsel. In this role, Mr. Srivastava will lead legal and compliance functions for the company as it grows its therapeutics and diagnostics businesses through R&D and new development and commercial partnerships. 

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today will announce new data from a phase 2a clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held January 18-20, 2024, in San Francisco, Calif.